title: A high-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes.
abstract: Vascular endothelial growth factors receptor 2 (VEGFR-2) has been implicated in playing an important role in the formation of new blood vessels in tumors and other diseases. A high affinity human/mouse cross-reactive anti-VEGFR-2 monoclonal antibody (mAb) named A8H1 was established by hybridoma technology. Several immunological methods were used to characterize the A8H1, including ELISA, affinity and kinetics assay, MALDI-TOF MS, WB, IP, IF, FASC and IHC. The results suggested that A8H1 could bind with linear and conformational epitopes of the VEGFR-2 antigen. The mAb had good specific reactivity with three forms of VEGFR-2 in HUVEC, and two forms in NIH-3T3 mouse fibroblast cells, which are regarded as non-expressive for VEGFR-2. The A8H1 mAb associated with intracellular and plasma membranes in HUVEC and with the nuclei in NIH-3T3 cells. This mAb also effectively identified VEGFR-2 over-expressing cells in a number of archived human cancer tissues.
authors.affiliation: Key Laboratory of Antibody Technique of Ministry of Health, Department of Pathology, Nanjing Medical University, 210029, Nanjing, China.
authors.forename: Jianfei
authors.initials: J
authors.lastname: Huang
authors.forename: Yang
authors.initials: Y
authors.lastname: Tan
authors.forename: Qi
authors.initials: Q
authors.lastname: Tang
authors.forename: Xinjian
authors.initials: X
authors.lastname: Liu
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Guan
authors.forename: Zhenqing
authors.initials: Z
authors.lastname: Feng
authors.forename: Jin
authors.initials: J
authors.lastname: Zhu
references.citation: Hum Pathol. 2007 Oct;38(10):1532-46
references.pmid: 17640715
references.citation: Oncogene. 1997 May 1;14(17):2079-89
references.pmid: 9160888
references.citation: Thromb Haemost. 2008 Apr;99(4):647-50
references.pmid: 18392318
references.citation: Biochim Biophys Acta. 2000 Jun 1;1466(1-2):71-8
references.pmid: 10825432
references.citation: Nat Rev Cancer. 2002 Oct;2(10):795-803
references.pmid: 12360282
references.citation: Curr Drug Targets. 2009 Feb;10(2):158-75
references.pmid: 19199912
references.citation: J Biol Chem. 1992 Mar 25;267(9):6093-8
references.pmid: 1556117
references.citation: Cancer Lett. 1999 Mar 1;136(2):203-13
references.pmid: 10355750
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4368-80
references.pmid: 12409337
references.citation: Expert Opin Investig Drugs. 2007 Jan;16(1):83-107
references.pmid: 17155856
references.citation: Acta Pharmacol Sin. 2004 Oct;25(10):1292-8
references.pmid: 15456530
references.citation: Cancer Metastasis Rev. 1998 Jun;17(2):155-61
references.pmid: 9770111
references.citation: Front Biosci. 2005 May 01;10:1415-39
references.pmid: 15769635
references.citation: Leukemia. 2003 Mar;17(3):604-11
references.pmid: 12646950
references.citation: Nature. 1975 Aug 7;256(5517):495-7
references.pmid: 1172191
references.citation: Mol Pharm. 2009 Jan-Feb;6(1):285-94
references.pmid: 19099493
references.citation: Curr Pharm Des. 2008;14(27):2883-91
references.pmid: 18991706
references.citation: EXS. 2005;(94):209-31
references.pmid: 15617481
references.citation: J Drug Target. 2007 Nov;15(9):623-31
references.pmid: 17968716
references.citation: Histopathology. 2003 Jul;43(1):33-9
references.pmid: 12823710
references.citation: Curr Med Chem. 2007;14(23):2495-516
references.pmid: 17979703
references.citation: Biotechnol Lett. 2008 Aug;30(8):1303-10
references.pmid: 18418716
references.citation: J Immunol Methods. 2004 May;288(1-2):149-64
references.pmid: 15183093
references.citation: J Immunol Methods. 2005 May;300(1-2):146-59
references.pmid: 15946674
references.citation: Cell Struct Funct. 2001 Feb;26(1):25-35
references.pmid: 11345501